A study by researchers at Washington University School of Medicine yields clues to why certain parts of the brain are particularly vulnerable to Alzheimer’s damage. It comes down to the gene APOE, the greatest genetic risk factor for Alzheimer’s disease.
Rejuvenating the immune cells that live in tissues surrounding the brain improves fluid flow and waste clearance from the brain — and may help treat or even prevent neurodegenerative diseases such as Alzheimer’s and Parkinson’s, according to a study by researchers at Washington University School of Medicine.
Carlos Cruchaga, at the School of Medicine, has received a 2022 Zenith Fellow Award from the Alzheimer’s Association. The annual award is given to scientists who have made significant contributions to Alzheimer’s disease research and are likely to continue to do so.
A five-year $9 million grant from the National Institutes of Health (NIH) will fund research led by investigators at Washington University School of Medicine and at the University of Texas at San Antonio to answer how so-called transposable elements in DNA can influence Alzheimer’s disease.
When people participate in studies of aging, they often want to know what their individual risks of developing dementia from Alzheimer’s disease are. Washington University researchers have developed an algorithm that can help provide them with information about what their risks may be.
Washington University School of Medicine is joining the National Institutes of Health (NIH)’s Bridge2AI program, an estimated $130 million initiative. One project aims to develop a framework for using artificial intelligence to diagnose disease based on the sound of patients’ voices.
Washington University School of Medicine researchers have found a new druggable pathway, in mice, that potentially could be used to help prevent Alzheimer’s dementia.
The Tracy Family SILQ Center for Neurodegenerative Biology has been established at the School of Medicine. The center aims to help researchers discover, study and validate biomarkers of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with a goal of identifying new drug targets and creating better diagnostic and prognostic tests.
A research group led by Rohit Pappu in the McKelvey School of Engineering and Anthony Hyman at the Max Planck Institute have discovered a new, relevant level of structure in cells.
Three of four blood tests used to identify people in early stages of Alzheimer’s disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine. Such differences may put Black patients at risk of misdiagnosis.